Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
| Autor: | Ulrich Mey, Adrian Schmidt, K. Eckhardt, Felicitas Hitz, Thomas Pabst, Simona Berardi Vilei, Clemens B. Caspar, Panagiotis Samaras, Fatime Krasniqi, Christian Rothermundt, Milica Enoiu, Emanuele Zucca, Nicolas Mach, Anne Cairoli, Natalie Fischer, Stephanie Rondeau |
|---|---|
| Přispěvatelé: | University of Zurich, Hitz, Felicitas |
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Bendamustine medicine.medical_specialty Lymphoma B-Cell medicine.medical_treatment 2720 Hematology 610 Medicine & health Aggressive lymphoma Sudden death 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Bendamustine Hydrochloride Humans Anthracyclines B-cell lymphoma Lenalidomide Aged Aged 80 and over Salvage Therapy Chemotherapy business.industry Remission Induction Hematology Middle Aged medicine.disease Thalidomide Surgery Survival Rate Regimen 030220 oncology & carcinogenesis 10032 Clinic for Oncology and Hematology Female Rituximab business 030215 immunology medicine.drug |
| Zdroj: | British Journal of Haematology. 174:255-263 |
| ISSN: | 0007-1048 |
| DOI: | 10.1111/bjh.14049 |
| Popis: | An increasing number of older patients are suffering from aggressive lymphoma. Effective and more tolerable treatment regimens are urgently needed for this growing patient population. Patients with aggressive lymphoma not eligible for anthracycline-based first-line therapy or intensive salvage regimens were treated with the rituximab-bendamustine-lenalidomide (R-BL) regimen (rituximab 375 mg/m(2) day 1, bendamustine 70 mg/m(2) d 1, 2, lenalidomide 10 mg d 1-21) for six cycles every 4 weeks. Forty-one patients with a median age of 75 (range 40-94) years were enrolled: 33 patients had substantial co-morbidities. 13 patients were not eligible for anthracycline-based first-line chemotherapy, 28 patients had relapsed/refractory disease. The primary endpoint, overall response, was achieved by 25 (61%) patients (95% confidence interval 45-76%). Grade ≥ 3 toxicity comprised haematological (59%), skin (15%), constitutional (15%) and neurological (12%) events. 9 patients died during trial treatment: 5 from lymphoma progression, 2 from toxicity, 2 with sudden death. After a median follow-up of 25·9 (interquartile range 20·4-31·6) months, 13 patients were still alive. Median overall survival was 14·5 months. In conclusion, R-BL can be considered a treatment option for elderly patients with treatment naïve or relapsed/refractory aggressive lymphoma not eligible for standard aggressive regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text